News
Protalix and Chiesi gain positive opinion for pegunigalsidase alfa
Chiesi Global Rare Diseases and Protalix BioTherapeutics have announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for PRX-102.